Sadeghi Masoumeh, Salehi-Abargouei Amin, Kasaei Zahra, Sajjadieh-Khajooie Hamidreza, Heidari Ramin, Roohafza Hamidreza
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Yazd, Iran.
Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
J Res Med Sci. 2016 Mar 15;21:18. doi: 10.4103/1735-1995.178757. eCollection 2016.
Although the effect of cardiac rehabilitation (CR) on cardiovascular disease (CVD) prognosis has been well-documented by several systematic reviews, none have focused on the effect of CR on metabolic syndrome (MetS) and its related components. Therefore, the present systematic review and meta-analysis was conducted to assess the effect of CR on MetS and its components.
PubMed, SCOPUS, Cochrane library, and Google Scholar database were searched up to February 2014 with no date and language restrictions. The random effects model was used to assess the overall effect of CR on MetS prevalence and the change in metabolic or anthropometric measures.
Fifteen studies with 19,324 subjects were included in the present systematic review and meta-analysis. Our analysis showed that the CR could significantly reduce MetS prevalence [reduction rate: 0.25, 95% confidence interval (CI): 0.21, 0.3, value <0.001; value for heterogeneity <0.001, I-squared: 86.2%]. Additionally, results showed the protective role of CR on all MetS components including high density lipoprotein cholesterol [mean difference (MD): 2.13 mg/dL, 95% CI: 1.17, 3.1], triglyceride (MD: -27.45 mg/dL, 95% CI: -36.92, -17.98), systolic blood pressure (SBP) (MD: -6.20 mmHg, 95% CI: -8.41, -3.99), diastolic blood pressure (DBP) (MD: -2.53 mmHg, 95% CI: -3.64, -1.41), fasting blood sugar (FBS) (MD: -6.42 mg/dL, 95% CI: -6.85, -5.99), and waist circumference (WC) (MD: -2.25 cm, 95% CI: -3.15, -1.35).
CR has resulted in improvement in MetS and its entire components, and could be considered as a useful tool for MetS patients, especially among those with CVD.
尽管多项系统评价已充分证明心脏康复（CR）对心血管疾病（CVD）预后的影响，但尚无研究关注CR对代谢综合征（MetS）及其相关组分的影响。因此，本系统评价和荟萃分析旨在评估CR对MetS及其组分的影响。
检索截至2014年2月的PubMed、SCOPUS、Cochrane图书馆和谷歌学术数据库，无日期和语言限制。采用随机效应模型评估CR对MetS患病率以及代谢或人体测量指标变化的总体影响。
本系统评价和荟萃分析纳入了15项研究，共19324名受试者。我们的分析表明，CR可显著降低MetS患病率[降低率：0.25，95%置信区间（CI）：0.21，0.3，P值<0.001；异质性P值<0.001，I²：86.2%]。此外，结果显示CR对所有MetS组分均具有保护作用，包括高密度脂蛋白胆固醇[平均差值（MD）：2.13mg/dL，95%CI：1.17，3.1]、甘油三酯（MD：-27.45mg/dL，95%CI：-36.92，-17.98）、收缩压（SBP）（MD：-6.20mmHg，95%CI：-8.41，-3.99）、舒张压（DBP）（MD：-2.53mmHg，95%CI：-3.64，-1.41）、空腹血糖（FBS）（MD：-6.42mg/dL，95%CI：-6.85，-5.99）和腰围（WC）（MD：-2.25cm，95%CI：-3.15，-1.35）。
CR可改善MetS及其所有组分，可被视为MetS患者，尤其是CVD患者的有效治疗手段。
